Wall Street Zen Initiates Coverage on Evogene (NASDAQ:EVGN)

Research analysts at Wall Street Zen assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Evogene in a report on Friday, March 7th.

Evogene Stock Up 0.0%

Evogene stock opened at $1.19 on Wednesday. The business has a 50 day moving average price of $1.18 and a two-hundred day moving average price of $1.44. The stock has a market cap of $6.36 million, a price-to-earnings ratio of -0.27 and a beta of 1.55. Evogene has a 12 month low of $0.95 and a 12 month high of $9.00.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $2.44 million during the quarter, compared to analysts’ expectations of $4.42 million.

Hedge Funds Weigh In On Evogene

Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC raised its holdings in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Evogene by 5.9% in the 1st quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock worth $395,000 after buying an additional 17,743 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Evogene during the 4th quarter worth approximately $30,000. 10.40% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.